Kinase-activating mutations lead to increased tyrosine kinase activity in EGFR and are frequently present in NSCLC and glioblastoma but rarely in other types of cancers (Table 1) [7,8,12,13,14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.